

Electronic Acknowledgement Receipt

EFS ID:	7313576
Application Number:	10821718
International Application Number:	
Confirmation Number:	1509
Title of Invention:	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
First Named Inventor/Applicant Name:	Clyde L. Schultz
Customer Number:	51886
Filer:	Stephen R. Finch/Elizabeth Cullity
Filer Authorized By:	Stephen R. Finch
Attorney Docket Number:	RH01.701US
Receipt Date:	30-MAR-2010
Filing Date:	09-APR-2004
Time Stamp:	12:00:55
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$875
RAM confirmation Number	9653
Deposit Account	502121
Authorized User	FINCH,STEPHEN R

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		RH01-701US-response-for-filing093009_OA.pdf	67449 a31f29fb269002a54385da005a1281e391946c	yes	11
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Amendment/Req. Reconsideration-After Non-Final Reject		1		1
	Claims		2		5
	Applicant Arguments/Remarks Made in an Amendment		6		11
Warnings:					
Information:					
2	Affidavit/Dec/Exhibit after Notice of Appeal	RH01-701-Lazar-Declaration.pdf	282478 39143f56c4d4637a9f4131c3ca94667a9719197	no	2
Warnings:					
Information:					
3	Affidavit/Dec/Exhibit after Notice of Appeal	RH01-701-Shultz-dec.pdf	26079 4221a9f71d5989fb22a6e4c4d6a1c7abab3948c	no	1
Warnings:					
Information:					
4	Terminal Disclaimer Filed	RH01-701US-TermDisc-patent-executed.pdf	269930 100cc564b4d4254623584fb411baa40571b75	no	2
Warnings:					
Information:					
5	Terminal Disclaimer Filed	RH01-701US-TermDisc-appln-executed.pdf	279242 11257cc084e9780233da092705d584d218d4f4	no	2
Warnings:					
Information:					
6	Information Disclosure Statement (IDS) Filed (SB/08)	updated_IDS.pdf	614669 140dc98807ca38d5773a51340a52c392251b41c	no	6
Warnings:					

Information:					
7	NPL Documents	COLTHURST-BiomaterialsUsedinthePosteriorSegmentoftheEye.pdf	94510	no	1
Warnings:					
Information:					
8	NPL Documents	ZHANG-AngiogenicInhibitionMediatedbyaDNAzymeThatTargetsVascular.pdf	2039680	no	7
Warnings:					
Information:					
9	NPL Documents	RH01-704-032009-OA.pdf	3439732	no	27
Warnings:					
Information:					
10	NPL Documents	RH01-702-061009-FOA.pdf	887444	no	7
Warnings:					
Information:					
11	NPL Documents	RH01-704-110409-FOA.pdf	1447723	no	13
Warnings:					
Information:					
12	NPL Documents	RH01-702-122409-OA.pdf	1203530	no	10
Warnings:					
Information:					
13	NPL Documents	Aiello-SuppressionofRetinalNeovascularizationinvivobyInhibitionofVascularEndothelial.pdf	1202450	no	5
Warnings:					
Information:					
14	NPL Documents	Clark-AVascularEndothelialGrowthFactorAntagonistsProducedbytheHumanPlacenta.pdf	250904	no	9
Warnings:					
Information:					
15	NPL Documents	Duh-VascularEndothelialGrowthFactorandDiabetes.pdf	371645	no	8
Warnings:					

Information:					
16	NPL Documents	Flieger-DramaticImprovementinHereditaryHemorrhagicTelangiectasiaAfterTreatment.pdf	42706 cc7eaf6dc1eb6cd62b0ee559bdc245e36f03e9b6b	no	1
Warnings:					
Information:					
17	NPL Documents	Hazzard-InjectionofSolubleVascularEndothelialGrowthFactorReceptor1intothePreovulatory.pdf	837864 71eeeebfdd9947d0bacc248f8cc993c432d9f05a2	no	8
Warnings:					
Information:					
18	NPL Documents	Hetian-A NovelPeptidisolatedfromPhageDisplayLibraryInhibitsTumorGrowthandMetastasis.pdf	433946 b04b4b1ba6cd2263d6d3dd11eb5c5057b849575e0	no	6
Warnings:					
Information:					
19	NPL Documents	Inoue-IdentificationofaVascularEndothelialGrowthFactor-VEGF-Antagonist.pdf	306168 d9e2fc425e1ef17eb2d49af56d8ff8acbbacc8b3	no	5
Warnings:					
Information:					
20	NPL Documents	Kimura-VascularEndothelialGrowthFactorAntagonistReducesBrainEdemaFormation.pdf	406388 d3b9eabaf014a6d6dc0d8d5574099b7bce9f6c9f7	no	6
Warnings:					
Information:					
21	NPL Documents	Ozaki-BlockadeofVascularEndothelialCellGrowthFactorReceptorSignalingIsSufficienttoCompletely.pdf	996852 7d4b46d19ef1a32e69324cd2b5d0113dbf70d41	no	11
Warnings:					
Information:					
22	NPL Documents	Pisano-UndersulfatedLow-MolecularWeightGlycolSplitTheparinasanAntiangiogenicVEGF.pdf	269484 7c3c570980310118d6138d25e3e7766d70364b2	no	6
Warnings:					
Information:					
23	NPL Documents	Siemeister-AnAntagonisticVascularEndothelialGrowthFactor-VEGF-VariantInhibitsVEGF.pdf	245096 d9c4f170d211003348f99d30b15e21a7f498	no	5
Warnings:					
Information:					
24	NPL Documents	Soker-InhibitionofVascularEndothelialGrowthFactor-VEGF-inducedEndothelialCell.pdf	176362 e8bc2256ad02701d417ca35f3301841d85da79	no	7
Warnings:					

Information:					
25	NPL Documents	delAmo-CurrentandFutureOphthalmicDrugDeliverySystems-AShifttothePosteriorSegment.pdf	478775 c1426b78ac905a0b10b452d2a9875e1b15e9fe	no	9
Warnings:					
Information:					
26	NPL Documents	Fattal-OcularDeliveryofNucleicAcids-AntisenseOligonucleotidesAptamersandsiRNA.pdf	506815 c146104c8f46a2796193c9b95dc58b1f152a313	no	21
Warnings:					
Information:					
27	NPL Documents	Myles-RecentProgressinOcularDrugDeliveryforPosteriorSegmentDisease-EmphasisonTransscleral.pdf	383018 d90cf70b11b9ec13394e057ad669f49177adac5	no	17
Warnings:					
Information:					
28	NPL Documents	Schuch-InVivoAdministrationofVascularEndothelialGrowthFactor-VEGF-anditsAntagonist.pdf	2310962 64bbdb02016118dc3ab4579646cc3d54588c95f8	no	7
Warnings:					
Information:					
29	Fee Worksheet (PTO-875)	fee-info.pdf	33356 23bf0f1d67b0bbd6e025342eb0c4b01907c6a39	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			19905257		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					